Stock Data
$1.92 (2.11%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
BioNTech SE is a pioneering biotechnology firm from Mainz, Germany, known for its innovative work in developing immunotherapies for a range of serious diseases, including cancer and infectious diseases. The company is at the forefront of creating treatments such as vaccines and therapies, with several products in various stages of clinical trials targeting conditions like melanoma, prostate cancer, and lung cancer. BioNTech is also notable for its collaborations with major pharmaceutical companies, enhancing its research and development capabilities in the quest to combat challenging diseases.
COVID-19 vaccine sales fell 66% year over year, leaving total revenue of $105.6 million, missing expectations, as the oncology pivot absorbs the cost. Restructuring and write-downs pushed the operating loss to $948.1 million, with Phase 3 readouts for pumitamig, gotistobart and trastuzumab pamirtecan due in the second half of the year.
Management cut full-year 2026 guidance to 1.6-1.9 billion euros from 2.0-2.3 billion after Germany drew down existing COVID vaccine inventory instead of ordering more. Oncology now funds the future: six pivotal trials started in the first half, with Guido Oelkers taking over as CEO by February 2027.
42 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
